In last trading session, Pulmonx Corp (NASDAQ:LUNG) saw 0.5 million shares changing hands with its beta currently measuring 0.64. Company’s recent per share price level of $10.85 trading at $0.01 or 0.09% at ring of the bell on the day assigns it a market valuation of $415.66M. That closing price of LUNG’s stock is at a discount of -31.52% from its 52-week high price of $14.27 and is indicating a premium of 52.72% from its 52-week low price of $5.13. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.3 million shares which gives us an average trading volume of 214.53K if we extend that period to 3-months.
For Pulmonx Corp (LUNG), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.41 in the current quarter.
Pulmonx Corp (NASDAQ:LUNG) trade information
Upright in the green during last session for gaining 0.09%, in the last five days LUNG remained trading in the green while hitting it’s week-highest on Wednesday, 11/15/23 when the stock touched $10.85 price level, adding 5.07% to its value on the day. Pulmonx Corp’s shares saw a change of 28.71% in year-to-date performance and have moved 17.30% in past 5-day. Pulmonx Corp (NASDAQ:LUNG) showed a performance of 29.17% in past 30-days. Number of shares sold short was 1.3 million shares which calculate 6.77 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $14.83 to the stock, which implies a rise of 26.84% to its current value. Analysts have been projecting $12.00 as a low price target for the stock while placing it at a high target of $18.00. It follows that stock’s current price would drop -65.9% in reaching the projected high whereas dropping to the targeted low would mean a loss of -10.6% for stock’s current value.
Pulmonx Corp (LUNG) estimates and forecasts
Statistics highlight that Pulmonx Corp is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -11.93% of value to its shares in past 6 months, showing an annual growth rate of -3.77% while that of industry is 16.10. Apart from that, the company came lowering its revenue forecast for fiscal year 2023. The company is estimating its revenue growth to decrease by -7.90% in the current quarter and calculating -2.40% decrease in the next quarter. This year revenue growth is estimated to rise 26.00% from the last financial year’s standing.
5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $18.19 million for the same. And 4 analysts are in estimates of company making revenue of $17.83 million in the next quarter that will end on Mar 2024. Company posted $15.43 million and $13.49 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 17.90% while estimating it to be 32.20% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -32.10% during past 5 years. In 2023, company’s earnings growth rate is likely to be around -3.91% while estimates for its earnings growth in next 5 years are of 23.60%.
Pulmonx Corp is more likely to be releasing its next quarterly report on October 30 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Pulmonx Corp (NASDAQ:LUNG)’s Major holders
Insiders are in possession of 3.43% of company’s total shares while institution are holding 93.71 percent of that, with stock having share float percentage of 97.03%. Investors also watch the number of corporate investors in a company very closely, which is 93.71% institutions for Pulmonx Corp that are currently holding shares of the company. Primecap Management Company is the top institutional holder at LUNG for having 5.52 million shares of worth $72.36 million. And as of Jun 29, 2023, it was holding 14.51% of the company’s outstanding shares.
The second largest institutional holder is Point72 Asset Management, L.P., which was holding about 3.33 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 8.75% of outstanding shares, having a total worth of $43.6 million.
On the other hand, Primecap Odyssey Aggressive Growth Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jul 30, 2023, the former fund manager was holding 3.72 million shares of worth $52.06 million or 9.78% of the total outstanding shares. The later fund manager was in possession of 1.03 million shares on Jun 29, 2023, making its stake of worth around $13.48 million in the company or a holder of 2.70% of company’s stock.